Home > Oncology > WCLC 2022 > WCLC 2022 Congress Round-Up > NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC

NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC

Presented By
Dr Mariano Provencio, Hospital Universitario Puerta de Hierro-Majadahonda, Spain
Conference
WCLC 2022
Trial
Phase 2, NADIM II
Doi
https://doi.org/10.55788/c9f74b64
Neoadjuvant nivolumab plus chemotherapy was superior to chemotherapy alone in patients with resectable stage IIIA–IIIB non-small cell lung cancer (NSCLC) in terms of progression-free survival (PFS) and overall survival (OS). The phase 2 NADIM II trial is therefore the first clinical trial to demonstrate an OS benefit of nivolumab plus chemotherapy over chemotherapy alone in this population [1]. The NADIM II trial (NCT03838159) randomised 90 patients with resectable stage IIIA–IIIB NSCLC 2:1 to neoadjuvant nivolumab plus chemotherapy or chemotherapy alone. The primary analysis showed a benefit of the experimental treatment over chemotherapy alone with regard to pathologic complete response rates (pCR; 36.8% vs 6.9%; 95% CI 1.70–36.51; P=0.0068) [2]. At WCLC 2022, Dr Mariano Provencio (Hospital Universitario Puerta de Hierro-Majadahonda, Spain) presented the PFS ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on